The American behavioral health landscape is currently at a critical crossroads. As federal agencies—including the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Medicare & Medicaid Services (CMS), and the Health Resources and Services Administration (HRSA)—intensify their scrutiny of psychiatric prescribing practices, a contentious debate has emerged. At the heart of the discourse is the federal government’s push for “deprescribing”—the systematic reduction of psychiatric medication use—highlighted recently in the MAHA (Making Healthcare Accountable) Action Plan and a joint “Dear Colleague” letter from federal health leaders.
While the impulse to audit and curb the misuse of psychiatric drugs is rooted in a valid concern for patient safety, experts argue that a singular focus on reduction threatens to obscure a much more systemic failure: the chronic undertreatment of mental illness in the United States. According to Dr. Caroline Carney, a board-certified psychiatrist and internist, the focus must shift from merely prescribing less to prescribing better.
The Main Facts: Defining the Crisis
The federal government’s recent directives emphasize the importance of informed consent, shared decision-making, and the reduction of polypharmacy—the simultaneous use of multiple medications—particularly among vulnerable populations such as children in foster care and older adults in long-term care facilities.
However, the prevailing sentiment among clinical experts is that the government’s current trajectory risks an “overcorrection.” The core argument presented by advocates for reform is that the behavioral health system is not suffering from an excess of high-quality care; it is suffering from a desperate shortage of it. With mental health resources already stretched to their breaking point, policies that incentivize deprescribing without providing viable, evidence-based alternatives could inadvertently increase the risk of relapse, hospitalization, and mortality among those who rely on medication for stability.
Chronology of the Policy Shift
The momentum toward federal intervention began in response to growing concerns over the quality of care in state-regulated facilities.
- Early 2020s: Mounting data regarding the inappropriate use of antipsychotics in nursing homes and stimulant medications in pediatric foster care populations drew congressional attention.
- 2024: The publication of the MAHA Action Plan signaled a formalization of federal concerns regarding the clinical oversight of psychiatric drugs.
- Recent Months: The release of a joint “Dear Colleague” letter by SAMHSA, CMS, HRSA, and the Administration for Children and Families (ACF) explicitly outlined expectations for clinical oversight, emphasizing non-pharmacological interventions and the need for rigorous tapering protocols.
- The Current Climate: Industry leaders and clinical practitioners are now pushing back, suggesting that while the principles of the letter are sound, the implementation strategy fails to account for the reality of the front-line clinical environment.
Supporting Data: The Reality of Undertreatment
To understand the limitations of a “less is more” approach, one must look at the sobering statistics of American mental health. The data suggests that the primary issue is not that patients are receiving too much care, but that they are not receiving enough.
- Access Gaps: In 2022, fewer than 50% of adults living with a mental illness in the U.S. received any form of professional treatment.
- The MOUD Crisis: Medications for Opioid Use Disorder (MOUD)—which are widely considered the gold standard for treating addiction—are utilized by only 25% of the population suffering from Opioid Use Disorder (OUD).
- Primary Care Overload: A significant percentage of psychiatric prescribing is currently performed by primary care physicians. These clinicians, while dedicated, often lack the specialized psychiatric training required to manage complex, multi-layered mental health disorders.
- Workforce Shortages: The nation faces a persistent, deepening deficit of psychiatrists, psychologists, and specialized behavioral health nurses, leading to geographic disparities where care is essentially unavailable in rural and low-income urban areas.
Official Responses and Perspectives
The federal government’s stance is one of caution regarding medication safety. Their communication emphasizes that psychiatric medications—while sometimes necessary—carry significant risks, including metabolic changes, sedative effects, and the complications associated with polypharmacy.
Conversely, clinical leaders like Dr. Caroline Carney argue that these risks are best managed through clinical infrastructure, not bureaucratic mandates. “The goal should not be to prescribe less; it should be to prescribe better,” Dr. Carney notes.
The medical community’s response highlights that for conditions like schizophrenia, bipolar disorder, and treatment-resistant depression, medication is frequently the thin line between a patient’s stability and a life-altering crisis. When policymakers use broad, reductionist messaging, they risk stigmatizing necessary life-saving treatments, potentially discouraging patients from seeking the help they need.
The Implications of a Misaligned Strategy
If the federal government pursues a policy agenda centered narrowly on deprescribing, the downstream consequences could be severe.
The Risks of Abrupt Tapering
Deprescribing is not a simple administrative task; it is a complex clinical procedure. Abrupt or poorly managed tapering of psychiatric medications can trigger profound withdrawal symptoms. In the worst cases, these shifts lead to acute relapse, homelessness, incarceration, and even suicide. Policy that does not mandate strict clinical oversight during these transitions is inherently dangerous.
The “Alternatives” Gap
A major pillar of the federal argument is the promotion of non-pharmacological alternatives such as psychotherapy, intensive outpatient programs, and peer support. However, these services are currently characterized by:
- Inadequate Reimbursement: Many behavioral health services remain under-reimbursed compared to physical health procedures, discouraging providers from expanding these programs.
- Long Wait Times: Even in urban centers, waitlists for evidence-based psychotherapy can span months.
- Lack of Integration: Our current system treats mental health as a siloed entity rather than integrating it into the primary care model, where most patients first seek help.
A Better Path Forward: Systemic Solutions
Instead of creating new, fee-for-service incentives solely for the act of deprescribing—which would likely add an unnecessary layer of administrative burden to an already exhausted workforce—experts propose a more holistic approach:
- Standardized Clinical Care Pathways: Implementing pathways that guide clinicians through the entire treatment process—from diagnosis to prescribing, monitoring, and, when appropriate, tapering—ensures that care is evidence-based and individualized.
- Integrated Behavioral Health Models: By fostering collaborative care models, where psychiatrists and primary care clinicians work in tandem, the system can ensure that medication is managed within the context of a broader, supportive treatment plan.
- Strengthening Clinician Education: Rather than focusing on the number of prescriptions, policy should focus on the quality of education provided to the clinicians who write them, ensuring they are proficient in both pharmacological and non-pharmacological interventions.
- Shared Decision-Making: True accountability comes from fostering environments where patients are fully informed of the risks and benefits of their treatment, allowing them to be active participants in their recovery journey.
Conclusion: Reframing the Goal
The behavioral health crisis in America is a crisis of access and infrastructure. While the federal government’s desire to protect patients from unnecessary medication is noble, it must not become a substitute for the hard work of building a robust, accessible, and high-quality mental health system.
To achieve a future where every patient receives evidence-based, individualized care, we must stop viewing medication through the lens of a binary "prescribe vs. deprescribe" choice. Instead, we must commit to a system that prioritizes the patient’s overall wellness, providing a full continuum of care that integrates medication, psychotherapy, nutrition, and social support. Only by investing in the structural integrity of our behavioral health system can we move past the current impasse and deliver the outcomes that patients truly deserve.
Author Bio: Caroline Carney, MD, MSc, FAPA, FAPM, CPHQ, is a board-certified psychiatrist and internist. She serves as a senior advisor to the Healthsperien Center for Behavioral Health and is the CEO of Magellan Health. With nearly three decades of experience in clinical care, integrated care program development, and health policy, Dr. Carney is a leading voice in quality improvement and medical education.
